Insmed (INSM) Scheduled to Post Quarterly Earnings on Thursday

Insmed (NASDAQ:INSM - Get Free Report) is set to post its quarterly earnings results before the market opens on Thursday, October 31st. Analysts expect Insmed to post earnings of ($1.18) per share for the quarter. Insmed has set its FY 2024 guidance at EPS.Parties that are interested in registering for the company's conference call can do so using this link.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing analysts' consensus estimates of ($1.22) by ($0.72). The business had revenue of $90.34 million during the quarter, compared to analyst estimates of $87.95 million. The firm's revenue for the quarter was up 17.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.78) earnings per share. On average, analysts expect Insmed to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Insmed Price Performance

Shares of NASDAQ INSM traded down $0.23 during mid-day trading on Thursday, reaching $71.71. The company's stock had a trading volume of 805,025 shares, compared to its average volume of 2,303,742. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. Insmed has a 52 week low of $21.92 and a 52 week high of $80.53. The stock has a fifty day moving average of $73.98 and a two-hundred day moving average of $59.42. The firm has a market capitalization of $10.66 billion, a PE ratio of -13.76 and a beta of 1.11.

Wall Street Analyst Weigh In

Several research analysts have weighed in on INSM shares. UBS Group upped their price target on Insmed from $78.00 to $84.00 and gave the stock a "buy" rating in a research note on Friday, August 9th. Truist Financial upped their target price on shares of Insmed from $85.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, October 11th. HC Wainwright reiterated a "buy" rating and issued a $90.00 price target on shares of Insmed in a report on Thursday, August 29th. The Goldman Sachs Group increased their price objective on shares of Insmed from $74.00 to $102.00 and gave the company a "buy" rating in a report on Wednesday, July 10th. Finally, Stifel Nicolaus raised their price objective on Insmed from $74.00 to $88.00 and gave the company a "buy" rating in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $82.73.

Insider Transactions at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the sale, the insider now owns 100,100 shares in the company, valued at approximately $7,157,150. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, insider Martina M.D. Flammer sold 13,436 shares of the firm's stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the sale, the insider now directly owns 106,134 shares of the company's stock, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the company's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the completion of the transaction, the insider now directly owns 100,100 shares in the company, valued at $7,157,150. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 78,882 shares of company stock worth $5,765,446. 4.60% of the stock is currently owned by company insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.